Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section
Photo of William T Beck

William T Beck

UIC Distinguished Professor, Biopharmaceutical Sciences

Contact Information

833 South Wood Street (865)
335 PHARM
Chicago, IL 60612

Phone: (312) 996-0888

Fax: (312) 996-0098

Education

  • PhD, The George Washington University

Research Interests

Molecular pharmacology and genetics of anticancer drug action and tumor cell drug resistance. Action of and tumor cell resistance to inhibitors of the DNA topoisomerases. Molecular mechanisms of regulation of genes associated with multidrug resistance in cancer. Role of splicing factors in tumorigenesis and anticancer drug action.

Intellectual Contributions

Journal Article

  • Ho TT, He X, Mo YY, Beck WT. "Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.". International journal of biochemistry and molecular biology. 2016;7(2):27-47.
  • He X, Arslan AD, Ho TT, Yuan C, Stampfer MR, Beck WT. "Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties.". Oncogenesis. 2014;3:e84. doi:10.1038/oncsis.2013.47.
  • Gardeux V, Arslan AD, Achour I, Ho TT, Beck WT, Lussier YA. "Concordance of deregulated mechanisms unveiled in underpowered experiments: PTBP1 knockdown case study.". BMC medical genomics. 2014;7 Suppl 1:S1. doi:10.1186/1755-8794-7-S1-S1.
  • Xie Y, Natarajan K, Bauer KS, Nakanishi T, Beck WT, Moreci RS, Jeyasuria P, Hussain A, Ross DD. "Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1.". Biochimica et biophysica acta. 2013;1829(12):1288-99. doi:10.1016/j.bbagrm.2013.10.008.
  • Arslan AD, He X, Wang M, Rumschlag-Booms E, Rong L, Beck WT. "A high-throughput assay to identify small-molecule modulators of alternative pre-mRNA splicing.". Journal of biomolecular screening. 2013;18(2):180-90. doi:10.1177/1087057112459901.
  • Cho S, Lu M, He X, Ee PL, Bhat U, Schneider E, , Beck WT. "Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells.". Proceedings of the National Academy of Sciences of the United States of America. 2011;108(51):20778-83. doi:10.1073/pnas.1019452108.
  • Das SG, Srinivasan B, Hermanson DL, Bleeker NP, Doshi JM, Tang R, Beck WT, Xing C. "Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.". Journal of medicinal chemistry. 2011;54(16):5937-48. doi:10.1021/jm200764t.
  • Natarajan K, Xie Y, Nakanishi T, Beck WT, Bauer KS, Ross DD. "Identification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestine.". Biochimica et biophysica acta. 2011;1809(7):295-305. doi:10.1016/j.bbagrm.2011.06.004.
  • Chen CF, He X, Arslan AD, Mo YY, Reinhold WC, Pommier Y, Beck WT. "Novel regulation of nuclear factor-YB by miR-485-3p affects the expression of DNA topoisomerase IIα and drug responsiveness.". Molecular pharmacology. 2011;79(4):735-41. doi:10.1124/mol.110.069633.
  • He X, Arslan AD, Pool MD, Ho TT, Darcy KM, Coon JS, Beck WT. "Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer.". Oncogene. 2011;30(3):356-65. doi:10.1038/onc.2010.426.
  • Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, Safa AR, Beck WT, Erickson LC. "Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.". The Journal of pharmacology and experimental therapeutics. 2009;330(2):423-9. doi:10.1124/jpet.109.153551.
  • Wu F, Zhu S, Ding Y, Beck WT, Mo YY. "MicroRNA-mediated regulation of Ubc9 expression in cancer cells.". Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(5):1550-7. doi:10.1158/1078-0432.CCR-08-0820.
  • Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, Montrose MH, Beck WT, Erickson LC. "Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.". The Journal of pharmacology and experimental therapeutics. 2008;324(1):95-102. doi:10.1124/jpet.107.127704.
  • He X, Pool M, Darcy KM, Lim SB, Auersperg N, Coon JS, Beck WT. "Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro.". Oncogene. 2007;26(34):4961-8. doi:10.1038/sj.onc.1210307.
  • Wu F, Chiocca S, Beck WT, Mo YY. "Gam1-associated alterations of drug responsiveness through activation of apoptosis.". Molecular cancer therapeutics. 2007;6(6):1823-30. doi:10.1158/1535-7163.MCT-06-0771.
  • Mirski SE, Sparks KE, Friedrich B, Köhler M, Mo YY, Beck WT, Cole SP. "Topoisomerase II binds importin alpha isoforms and exportin/CRM1 but does not shuttle between the nucleus and cytoplasm in proliferating cells.". Experimental cell research. 2007;313(3):627-37. doi:10.1016/j.yexcr.2006.11.004.
  • Kamalakaran S, Radhakrishnan SK, Beck WT. "Identification of estrogen-responsive genes using a genome-wide analysis of promoter elements for transcription factor binding sites.". The Journal of biological chemistry. 2005;280(22):21491-7. doi:10.1074/jbc.M409176200.
  • Mo YY, Yu Y, Theodosiou E, Ee PL, Beck WT. "A role for Ubc9 in tumorigenesis.". Oncogene. 2005;24(16):2677-83. doi:10.1038/sj.onc.1208210.
  • Ee PL, He X, Ross DD, Beck WT. "Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.". Molecular cancer therapeutics. 2004;3(12):1577-83.
  • He X, Ee PL, Coon JS, Beck WT. "Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.". Clinical cancer research : an official journal of the American Association for Cancer Research. 2004;10(14):4652-60. doi:10.1158/1078-0432.CCR-03-0439.
  • Mo YY, Yu Y, Ee PL, Beck WT. "Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs.". Cancer research. 2004;64(8):2793-8.
  • Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. "Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.". Cancer research. 2004;64(4):1247-51.
  • Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, Beck WT. "Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene.". Cancer research. 2004;64(4):1247-51.
  • Rallabhandi P, Hashimoto K, Mo YY, Beck WT, Moitra PK, D'Arpa P. "Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin.". The Journal of biological chemistry. 2002;277(42):40020-6. doi:10.1074/jbc.M200388200.
  • Tavormina PA, Côme MG, Hudson JR, Mo YY, Beck WT, Gorbsky GJ. "Rapid exchange of mammalian topoisomerase II alpha at kinetochores and chromosome arms in mitosis.". The Journal of cell biology. 2002;158(1):23-9. doi:10.1083/jcb.200202053.
  • Mo YY, Yu Y, Shen Z, Beck WT. "Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein.". The Journal of biological chemistry. 2002;277(4):2958-64. doi:10.1074/jbc.M108263200.
  • Beck WT, Mo YY, Bhat UG. "Cytotoxic signalling by inhibitors of DNA topoisomerase II.". Biochemical Society transactions. 2001;29(Pt 6):702-3.
  • Cai L, Lim K, Ren S, Cadena RS, Beck WT. "Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexes.". Journal of medicinal chemistry. 2001;44(18):2959-65.
  • Morgan SE, Beck WT. "Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.". Molecular pharmacology. 2001;59(2):203-11.
  • Mo YY, Wang C, Beck WT. "A novel nuclear localization signal in human DNA topoisomerase I.". The Journal of biological chemistry. 2000;275(52):41107-13. doi:10.1074/jbc.M003135200.
  • Morgan SE, Kim R, Wang PC, Bhat UG, Kusumoto H, Lu T, Beck WT. "Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.". Oncogene. 2000;19(43):5010-9. doi:10.1038/sj.onc.1203865.
  • Mo YY, Wang P, Beck WT. "Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.". Experimental cell research. 2000;256(2):480-90. doi:10.1006/excr.2000.4864.
  • Morgan SE, Cadena RS, Raimondi SC, Beck WT. "Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.". Molecular pharmacology. 2000;57(2):296-307.
  • Beck WT, Morgan SE, Mo YY, Bhat UG. "Tumor cell resistance to DNA topoisomerase II inhibitors: new developments.". Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 1999;2(6):382-389. doi:10.1054/drup.1999.0110.
  • Khélifa T, Beck WT. "Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cells.". Biochemical pharmacology. 1999;58(8):1247-57.
  • Mo YY, Beck WT. "Association of human DNA topoisomerase IIalpha with mitotic chromosomes in mammalian cells is independent of its catalytic activity.". Experimental cell research. 1999;252(1):50-62. doi:10.1006/excr.1999.4616.
  • Bhat UG, Raychaudhuri P, Beck WT. "Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.". Proceedings of the National Academy of Sciences of the United States of America. 1999;96(14):7859-64.
  • Khélifa T, Beck WT. "Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease.". Molecular pharmacology. 1999;55(3):548-56.
  • Mo YY, Beck WT. "DNA damage signals induction of fas ligand in tumor cells.". Molecular pharmacology. 1999;55(2):216-22.
  • Wang Q, Beck WT. "Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53.". Cancer research. 1998;58(24):5762-9.
  • Mo YY, Ameiss KA, Beck WT. "Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein.". BioTechniques. 1998;25(6):1052-7.
  • Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH. "Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.". Biochemical pharmacology. 1998;56(6):719-27.
  • Dolan ME, Frydman B, Thompson CB, Diamond AM, Garbiras BJ, Safa AR, Beck WT, Marton LJ. "Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents.". Anti-cancer drugs. 1998;9(5):437-48.
  • Mo YY, Wang Q, Beck WT. "Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.". Cancer research. 1997;57(22):5004-8.
  • Beck WT, Grogan TM. "Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins.". Leukemia. 1997;11(7):1107-9.
  • Scheltema JM, Romijn JC, van Steenbrugge GJ, Beck WT, Schröder FH, Mickisch GH. "Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide.". Journal of cancer research and clinical oncology. 1997;123(10):546-54.
  • Mo YY, Beck WT. "Heterogeneous expression of DNA topoisomerase II alpha isoforms in tumor cell lines.". Oncology research. 1997;9(4):193-204.
  • Beck WT, Khélifa T, Kusumoto H, Mo YY, Rodgers Q, Wolverton JS, Wang Q. "Novel mechanisms of resistance to inhibitors of DNA topoisomerases.". Advances in enzyme regulation. 1997;37:17-26.
  • Hofmann J, Utz I, Spitaler M, Hofer S, Rybczynska M, Beck WT, Herrmann DB, Grunicke H. "Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).". British journal of cancer. 1997;76(7):862-9.
  • Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, Andreeff M, Bates SE, Berard CW, Boyett JM, Brophy NA, Broxterman HJ, Chan HS, Dalton WS, Dietel M, Fojo AT, Gascoyne RD, Head D, Houghton PJ, Srivastava DK, Lehnert M, Leith CP, Paietta E, Pavelic ZP, Weinstein R. "Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.". Cancer research. 1996;56(13):3010-20.
  • Nitiss JL, Beck WT. "Antitopoisomerase drug action and resistance.". European journal of cancer (Oxford, England : 1990). 1996;32A(6):958-66.
  • Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT. "Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.". Cancer research. 1996;56(11):2573-83.
  • Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. "P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(3):886-900.
  • Schuetz EG, Beck WT, Schuetz JD. "Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.". Molecular pharmacology. 1996;49(2):311-8.
  • Bhat UG, Winter MA, Pearce HL, Beck WT. "A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line.". Molecular pharmacology. 1995;48(4):682-9.
  • Chen M, Beck WT. "Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26.". Cancer research. 1995;55(7):1509-16.
  • Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. "Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.". Cytometry. 1995;19(2):134-45. doi:10.1002/cyto.990190208.
  • Hashimoto S, Danks MK, Chatterjee S, Beck WT, Berger NA. "A novel point mutation in the 3' flanking region of the DNA-binding domain of topoisomerase II alpha associated with acquired resistance to topoisomerase II active agents.". Oncology research. 1995;7(1):21-9.
  • Chen M, Beck WT. "DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines.". Oncology research. 1995;7(2):103-11.
  • Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. "Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26.". Biochemical pharmacology. 1994;48(9):1785-95.
  • Kim R, Beck WT. "Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.". Cancer research. 1994;54(18):4958-66.
  • Kumagai M, Manabe A, Coustan-Smith E, Blakley RL, Beck WT, Santana VM, Behm FG, Raimondi SC, Campana D. "Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia.". Leukemia. 1994;8(7):1116-23.
  • Mariani M, Capolongo L, Suarato A, Bargiotti A, Mongelli N, Grandi M, Beck WT. "Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.". Investigational new drugs. 1994;12(2):93-7.
  • Beck WT, Kim R, Chen M. "Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.". Cancer chemotherapy and pharmacology. 1994;34 Suppl:S14-8.
  • Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R, Suttle DP. "Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II.". Advances in pharmacology (San Diego, Calif.). 1994;29B:145-69.
  • Chen M, Beck WT. "Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.". Cancer research. 1993;53(24):5946-53.
  • Hill AB, Trent JM, Thompson FH, Danks MK, Beck WT. "Loss of tumorigenicity in a methotrexate-resistant human leukemia cell line.". Cancer genetics and cytogenetics. 1993;70(1):48-55.
  • Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT, Roninson IB. "Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA.". Proceedings of the National Academy of Sciences of the United States of America. 1993;90(8):3231-5.
  • Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker WG, Zwelling LA, Futscher BW, Suttle DP, Beck WT. "Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.". Cancer research. 1993;53(6):1373-9.
  • Beck WT, Danks MK, Wolverton JS, Granzen B, Chen M, Schmidt CA, Bugg BY, Friche E, Suttle DP. "Altered DNA topoisomerase II in multidrug resistance.". Cytotechnology. 1993;11(2):115-9.
  • Beck WT, Danks MK, Wolverton JS, Kim R, Chen M. "Drug resistance associated with altered DNA topoisomerase II.". Advances in enzyme regulation. 1993;33:113-27.
  • Friche E, Danks MK, Beck WT. "Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.". Cancer research. 1992;52(20):5701-6.
  • Wolverton JS, Danks MK, Granzen B, Beck WT. "DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.". Cancer research. 1992;52(15):4248-53.
  • Beck WT, Qian XD. "Photoaffinity substrates for P-glycoprotein.". Biochemical pharmacology. 1992;43(1):89-93.
  • Granzen B, Graves DE, Baguley BC, Danks MK, Beck WT. "Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.". Oncology research. 1992;4(11-12):489-96.
  • Kessel D, Beck WT, Kukuruga D, Schulz V. "Characterization of multidrug resistance by fluorescent dyes.". Cancer research. 1991;51(17):4665-70.
  • Bugg BY, Danks MK, Beck WT, Suttle DP. "Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.". Proceedings of the National Academy of Sciences of the United States of America. 1991;88(17):7654-8.
  • Friche E, Danks MK, Schmidt CA, Beck WT. "Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.". Cancer research. 1991;51(16):4213-8.
  • Beck WT, Danks MK. "Mechanisms of resistance to drugs that inhibit DNA topoisomerases.". Seminars in cancer biology. 1991;2(4):235-44.
  • Beck WT. "Modulators of P-glycoprotein-associated multidrug resistance.". Cancer treatment and research. 1991;57:151-70.
  • Beck WT. "Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.". Cancer treatment reviews. 1990;17 Suppl A:11-20.
  • Qian XD, Beck WT. "Progesterone photoaffinity labels P-glycoprotein in multidrug-resistant human leukemic lymphoblasts.". The Journal of biological chemistry. 1990;265(31):18753-6.
  • Fernandes DJ, Danks MK, Beck WT. "Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA.". Biochemistry. 1990;29(17):4235-41.
  • Beck WT. "Multidrug resistance and its circumvention.". European journal of cancer (Oxford, England : 1990). 1990;26(4):513-5.
  • Qian XD, Beck WT. "Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.". Cancer research. 1990;50(4):1132-7.
  • Beck WT. "Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II.". Bulletin du cancer. 1990;77(11):1131-41.
  • Pearce HL, Winter MA, Beck WT. "Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance.". Advances in enzyme regulation. 1990;30:357-73.
  • Thimmaiah KN, Horton JK, Qian XD, Beck WT, Houghton JA, Houghton PJ. "Structural determinants of phenoxazine type compounds required to modulate the accumulation of vinblastine and vincristine in multidrug-resistant cell lines.". Cancer communications. 1990;2(7):249-59.
  • Ubezio P, Limonta M, D'Incalci M, Damia G, Masera G, Giudici G, Wolverton JS, Beck WT. "Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphocytic leukaemia.". European journal of cancer & clinical oncology. 1989;25(12):1895-9.
  • Beck WT. "Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance.". Journal of the National Cancer Institute. 1989;81(22):1683-5.
  • Cass CE, Janowska-Wieczorek A, Lynch MA, Sheinin H, Hindenburg AA, Beck WT. "Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.". Cancer research. 1989;49(21):5798-804.
  • Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC, Beck WT. "Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.". Proceedings of the National Academy of Sciences of the United States of America. 1989;86(13):5128-32.
  • Wolverton JS, Danks MK, Schmidt CA, Beck WT. "Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.". Cancer research. 1989;49(9):2422-6.
  • Danks MK, Schmidt CA, Deneka DA, Beck WT. "Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.". Cancer communications. 1989;1(2):101-9.
  • Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT. "Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.". Biochemistry. 1988;27(24):8861-9.
  • Beck WT, Cirtain MC, Glover CJ, Felsted RL, Safa AR. "Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.". Biochemical and biophysical research communications. 1988;153(3):959-66.
  • Zamora JM, Pearce HL, Beck WT. "Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.". Molecular pharmacology. 1988;33(4):454-62.
  • Lee SC, Deutsch C, Beck WT. "Comparison of ion channels in multidrug-resistant and -sensitive human leukemic cells.". Proceedings of the National Academy of Sciences of the United States of America. 1988;85(6):2019-23.
  • Hill AB, Beck WT, Trent JM. "Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.". Cancer research. 1988;48(2):393-8.
  • Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM. "Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.". Cancer research. 1987;47(20):5455-60.
  • Beck WT. "The cell biology of multiple drug resistance.". Biochemical pharmacology. 1987;36(18):2879-87.
  • Kelner MJ, McMorris TC, Beck WT, Zamora JM, Taetle R. "Preclinical evaluation of illudins as anticancer agents.". Cancer research. 1987;47(12):3186-9.
  • Danks MK, Yalowich JC, Beck WT. "Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).". Cancer research. 1987;47(5):1297-301.
  • Zamora JM, Beck WT. "Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells.". Biochemical pharmacology. 1986;35(23):4303-10.
  • Beck WT, Cirtain MC, Ashmun RA, Mirro J. "Differentiation and the multiple drug resistance phenotype in human leukemic cells.". Cancer research. 1986;46(9):4571-5.
  • Beck WT, Cirtain MC, Look AT, Ashmun RA. "Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.". Cancer research. 1986;46(2):778-84.
  • Beck WT, Danks MK, Cirtain MC, van Heiningen JN. "Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.". Progress in clinical and biological research. 1986;223:3-10.
  • Danks MK, Metzger DW, Ashmun RA, Beck WT. "Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.". Cancer research. 1985;45(7):3220-4.
  • Conter V, Beck WT. "Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine.". Cancer treatment reports. 1984;68(6):831-9.
  • Beck WT. "Cellular pharmacology of Vinca alkaloid resistance and its circumvention.". Advances in enzyme regulation. 1984;22:207-27.
  • Beck WT, Cirtain MC, Lefko JL. "Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.". Molecular pharmacology. 1983;24(3):485-92.
  • Beck WT. "Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts.". Cancer treatment reports. 1983;67(10):875-82.
  • Conter V, Beck WT. "Impairment by ruthenium red of anticancer drug cytotoxicity in CCRF-CEM cells.". Biochemical pharmacology. 1983;32(4):723-6.
  • Katze JR, Beck WT, Cheng CS, McCloskey JA. "Why is tumor tRNA hypomodified with respect to Q nucleoside?". Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 1983;84:146-59.
  • Beck WT, Dedmon ML, Ouellette MA. "Biochemical basis for impaired drug metabolism in tumor-bearing rats. Evidence for altered regulation of hepatic microsomal hemeprotein synthesis.". Biochemical pharmacology. 1982;31(8):1535-43.
  • Beck WT, Cirtain MC. "Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.". Cancer research. 1982;42(1):184-9.
  • Katze JR, Beck WT. "Administration of queuine to mice relieves modified nucleoside queuosine deficiency in Ehrlich ascites tumor tRNA.". Biochemical and biophysical research communications. 1980;96(1):313-9.
  • Beck WT. "Increase by vinblastine of oxidized glutathione in cultured mammalian cells.". Biochemical pharmacology. 1980;29(17):2333-7.
  • Beck WT, Mueller TJ, Tanzer LR. "Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.". Cancer research. 1979;39(6 Pt 1):2070-6.
  • Chou JT, Beck WT, Khwaja T, Mayer K, Lien E. "Synthesis and anticancer activity of novel cyclic N-hydroxyureas.". Journal of pharmaceutical sciences. 1977;66(11):1556-61.
  • Beck WT, Mandel HG, Fabro S. "Physiological disposition of pentobarbital in tumor-bearing mice.". Cancer research. 1975;35(5):1333-40.
  • Beck WT, Bellantone RA, Canellakis ES. "Puromycin stimulation of rat liver ornithine decarboxylase activity.". Nature. 1973;241(5387):275-7.
  • Beck WT, Bellantone RA, Canellakis ES. "The in vivo stimulation of rat liver ornithine decarboxylase activity by dibutyryl cyclic adenosine 3',5'-monophosphate, theophylline and dexamethasone.". Biochemical and biophysical research communications. 1972;48(6):1649-55.

Other

  • Beck WT. (1996). "Unanswered questions about multidrug resistance.". Cytotechnology. Vol. 19. Issue 3. Page(s) 177-9.
  • Beck WT. (1995). "Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: clinical potential or experimental artifact?". Journal of the National Cancer Institute. Vol. 87. Issue 2. Page(s) 73-5.
  • Beck WT, Kuttesch JF. (1992). "Neurological symptoms associated with cyclosporin plus doxorubicin.". Lancet. Vol. 340. Issue 8817. Page(s) 496.
  • Beck WT. (1991). "Do anti-P-glycoprotein antibodies have a future in the circumvention of multidrug resistance?". Journal of the National Cancer Institute. Vol. 83. Issue 19. Page(s) 1364-6.
Top